Provided by Tiger Trade Technology Pte. Ltd.

Purple Biotech Ltd.

1.75
-0.2300-11.62%
Post-market: 1.66-0.0900-5.14%19:59 EDT
Volume:357.34K
Turnover:687.36K
Market Cap:2.85M
PE:-0.06
High:2.10
Open:2.02
Low:1.73
Close:1.98
52wk High:14.10
52wk Low:1.16
Shares:1.63M
Float Shares:1.62M
Volume Ratio:0.02
T/O Rate:22.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-28.8060
EPS(LYR):-54.9640
ROE:-111.13%
ROA:-20.31%
PB:0.23
PE(LYR):-0.03

Loading ...

Top Midday Gainers

MT Newswires Live
·
Sep 03

Why Is Purple Biotech (PPBT) Stock 42% Up Today?

TIPRANKS
·
Sep 02

Purple Biotech issued notice of allowance from USPTO

TIPRANKS
·
Sep 02

Press Release: Purple Biotech Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 07

Purple Biotech Ltd Expected to Post a Loss of 40 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Purple Biotech Says Preclinical Study Supports Advancing IM1240 to First-in-Human Trial in 2027

MT Newswires Live
·
Jun 11

Purple Biotech presents new IM1240 data at EACR

TIPRANKS
·
Jun 11

Purple Biotech files $200M mixed securities shelf

TIPRANKS
·
May 21

Purple Biotech Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 19

Analysts Are Bullish on These Healthcare Stocks: Purple Biotech (PPBT), Satellos Bioscience (MSLE)

TIPRANKS
·
May 18

Purple Biotech Ltd expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
May 15

Purple Biotech announces collaboration with Converge Bio

TIPRANKS
·
Mar 25

Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)

TIPRANKS
·
Mar 20

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

TIPRANKS
·
Mar 20

Purple Biotech regains compliance with Nasdaq

TIPRANKS
·
Mar 17

Israel's Purple Biotech Q4 net loss widens on impairment charge

Reuters
·
Mar 13

Press Release: Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

Dow Jones
·
Mar 13

Purple Biotech Ltd expected to post a loss of $3.40 a share - Earnings Preview

Reuters
·
Mar 13